ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Executive Network Partnering Corporation

Executive Network Partnering Corporation (ENPC)

9.25
0.00
(0.00%)
Closed July 29 4:00PM
9.25
0.00
( 0.00% )
Pre Market: 8:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
9.25
Bid
-
Ask
-
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
9.25
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

ENPC Latest News

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated1There is an urgent need to develop new therapies...

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HWMHowmet Aerospace Inc
$ 93.00
(12.25%)
22.2k
EOIEaton Vance Enhanced Equity Income Fund
$ 21.13
(12.10%)
36
BYONBeyond Inc
$ 14.94
(9.93%)
149.51k
MHOMI Homes Inc
$ 179.9955
(8.00%)
761
FBMSFirst Bancshares Inc
$ 32.99
(7.70%)
3.88k
SMRTSmartRent Inc
$ 1.89
(-21.25%)
38.08k
AGCOAGCO Corp
$ 93.00
(-8.87%)
25.97k
BYDBoyd Gaming Corp
$ 56.72
(-7.76%)
26
RYIRyerson Holding Corporation
$ 23.52
(-6.96%)
160
GPKGraphic Packaging Holding Company
$ 26.08
(-6.89%)
536
PFEPfizer Inc
$ 31.41
(2.25%)
4.56M
UBERUber Technologies Inc
$ 64.07
(0.49%)
1.15M
CCitigroup Inc
$ 64.50
(0.31%)
892.55k
GLWCorning Inc
$ 40.02
(-6.23%)
810.93k
DELLDell Technologies Inc
$ 111.73
(0.48%)
798.23k

ENPC Discussion

View Posts
@LaughinPaulRyan @LaughinPaulRyan 4 years ago
CAPSTM Core Principles
Long-Term Orientation:

Focused on long-term share price performance and the interests of long-term common shareholders.

Partnership Model:

Focused on working with high quality existing owners and management teams who are not in need of operational improvements and have a desire to work together as partners.

Minimizing Dilution Costs:

Focused on minimizing dilution costs traditionally associated with special purpose acquisition companies, which can negatively impact the returns to long-term common shareholders and is cost prohibitive to many high quality companies who like the process of going public through a special purpose acquisition company but not the cost.

Economic Alignment From the Outset:

Focused on aligning economic interests at the time of the initial public offering, in order to facilitate an easier and more comfortable dialogue with a high-quality company, the management team and its existing owners.

Sustainable Value Creation:

Focused on share price appreciation which is measured over a long period of time and reflective of actual and sustainable value creation, as opposed to short-term trading price movements or a single price point.

Optimizing Banker Selection on an Independent Basis:

Focused on working with management and existing owners, on an independent basis, to optimize for the right banking team at the time of the partnering transaction as opposed to at the time of the initial public offering and avoiding potentially duplicative banker transaction costs, which are dilutive to long-term common shareholders, and potential conflicts.

Continued Ownership:

Focused on partnering with an existing owner who may want to continue ownership in a high quality asset but needs to provide liquidity to existing shareholders and/or limited partners. CAPS™ provides an ability to transition ownership to the public market, which is deeper and more liquid than the private market, in a disciplined fashion and for existing owners to share in the future upside potential over the long term.
👍️0